Skip to main content
Midas Edge

Sana Biotechnology, Inc.

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

SANA$2.43-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance as of December 31, 2022191,022$19$1,558,459$(4,327)$(1,054,836)$499,315
Issuance of common stock from at the market offering, net of issuance costs of $1,2134,586127,019--27,020
Vesting of restricted stock443-----
Exercise of stock options1,146-2,020--2,020
Issuance of common stock related to employee stock purchase plan660-2,606--2,606
Stock-based compensation expense--35,533--35,533
Unrealized gain on marketable securities, net---4,267-4,267
Net loss----(283,255)(283,255)
Balance as of December 31, 2023197,857$20$1,625,637$(60)$(1,338,091)$287,506
Issuance of common stock from at the market offering, net of issuance costs of $158150-992--992
Issuance of common stock from follow-on offering and accompanying pre-funded warrants, net of issuance costs of $9,74121,7732180,006--180,008
Vesting of restricted stock966-----
Exercise of stock options2,643-9,493--9,493
Issuance of common stock related to employee stock purchase plan534-1,512--1,512
Stock-based compensation expense--37,678--37,678
Unrealized gain on marketable securities, net---74-74
Net loss----(266,759)(266,759)
Balance as of December 31, 2024223,923$22$1,855,318$14$(1,604,850)$250,504
Issuance of common stock from at the market offering, net of issuance costs of $1,59811,298245,765--45,767
Issuance of common stock from common stock financings and accompanying pre-funded warrants, net of issuance costs of $5,62524,254280,623--80,625
Exercise of pre-funded warrants4,445-----
Vesting of restricted stock1,514-----
Exercise of stock options1,05912,325--2,326
Issuance of common stock related to employee stock purchase plan239-350--350
Stock-based compensation expense--25,464--25,464
Unrealized gain on marketable securities, net---14-14
Net loss----(244,166)(244,166)
Balance as of December 31, 2025266,732$27$2,009,845$28$(1,849,016)$160,884
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.